LUX Infusion

LUX Infusion, based in Anchorage, US, specializes in providing medical infusion services outside of hospital environments, offering a range of standard and specialty treatments for chronic illnesses and immunological disorders. Founded in 2022 and headquartered in Anchorage, Alaska, LUX Infusion operates in the medical infusion sector, providing services tailored to patients needing intravenous medications. The company has successfully completed one deal as of October 17, 2025, when it was acquired by BioMatrix, LLC. The acquisition aligns with BioMatrix, LLC's strategy to enhance service capabilities and market reach.

LUX Infusion specializes in providing medical infusion services in non-hospital settings, focusing on a variety of standard and specialty infusion treatments and injectable therapies. Their core offerings include infusion therapy for conditions requiring medications delivered intravenously, catering to patients with chronic illnesses and immunological disorders. The clinic emphasizes a patient-centered approach, working collaboratively with healthcare providers to develop individualized care plans that enhance patient comfort and satisfaction. LUX Infusion serves a diverse clientele, including individuals with private insurance, Medicare, and Medicaid, primarily within the geographical markets of Alaska, specifically Anchorage, Palmer, and Fairbanks.

The facility is designed to create a welcoming atmosphere, equipped with amenities such as heated and massage chairs, warm blankets, and aromatherapy to enhance the overall patient experience. LUX Infusion generates revenue through direct transactions with patients seeking infusion therapies, leveraging a model that focuses on providing high-quality medical services in a comfortable environment. Patients typically access their services through referrals from healthcare providers, with a structured approach to insurance pre-authorization facilitated by a dedicated Patient Navigator. The company’s offerings include various infusion treatments tailored to individual health needs, and the pricing structure accommodates both private pay and insurance-covered patients, ensuring affordability and accessibility.

Transactions include co-payments processed through insurance plans, reflecting the clinic's commitment to financial assistance and support for patients navigating the complexities of healthcare financing. The focus on individualized care and superior service enhances patient loyalty and retention, contributing to the clinic's revenue stability. In October 2025, LUX Infusion was acquired by BioMatrix, LLC, a portfolio company of ACON Investments, Triton Pacific Capital Partners, and Frazier Healthcare Partners. This acquisition is set to enhance service capabilities and expand market reach.

Future plans may include the launch of new infusion therapy products and potential geographical expansion into additional Alaskan markets. The integration with BioMatrix, LLC will likely utilize the recent funding to support these growth initiatives.